- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Protalix Biotherapeutics Inc (PLX)
Protalix Biotherapeutics Inc stock price live, this page displays NYSE PLX stock exchange data. View the PLX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Protalix Biotherapeutics Inc real time stock price chart below.
What Is the Protalix Biotherapeutics Inc Stock Price Today?
The Protalix Biotherapeutics Inc stock price today is 2.570.
What Is the Stock Symbol for Protalix Biotherapeutics Inc?
The stock symbol for Protalix Biotherapeutics Inc is ""PLX.""
What Stock Exchange Does Protalix Biotherapeutics Inc Trade On?
Protalix Biotherapeutics Inc is listed and trades on the NYSE stock exchange.
Is Protalix Biotherapeutics Inc a Good Stock to Buy?
Determining whether Protalix Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PLX quote. (ISIN: US74365A3095)
What Is the Protalix Biotherapeutics Inc Stock Price Today?
The Protalix Biotherapeutics Inc stock price today is 2.570.
What Is the Stock Symbol for Protalix Biotherapeutics Inc?
The stock symbol for Protalix Biotherapeutics Inc is ""PLX.""
What Stock Exchange Does Protalix Biotherapeutics Inc Trade On?
Protalix Biotherapeutics Inc is listed and trades on the NYSE stock exchange.
Is Protalix Biotherapeutics Inc a Good Stock to Buy?
Determining whether Protalix Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PLX quote. (ISIN: US74365A3095)
Fair Value
An estimate of a Protalix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.530
2.599
52 wk Range
0.990
3.100
PLX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Protalix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5302.599
52 wk Range
0.9903.100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PLX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Protalix's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
14.000
Upside
+444.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Form 8K Protalix Biotherapeutics Inc For: 22 August
- Investing.com
- Form 8K Protalix Biotherapeutics Inc For: 22 August
- Investing.com
- Form 8K Protalix Biotherapeutics Inc For: 21 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Protalix Biotherapeutics Inc Company Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix Biotherapeutics Inc Earnings Call Summary for Q2/2025
- Protalix (PLX) Q2 2025: EPS -$0.04 (136.36% miss), revenue $25.77M (11.56% beat). Stock fell 3.73% premarket.
- Revenue up 16% YoY, driven by Elfabrio sales. R&D expenses doubled to $6M, impacting profitability.
- Net income: $164,000, turnaround from $2.2M loss in Q2 2024. Cash and equivalents: $33.4M.
- PRX-115 Phase II study to begin enrollment in Q4 2025. Targeting $100M+ Elfabrio royalties by 2030.
- CEO expects up to $500M in milestone payments. No immediate M&A plans announced.
Last Updated: 14/08/2025, 14:26
Read Full TranscriptCompare PLX to Peers and Sector
Metrics to compare | PLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.7x | −4.0x | −0.7x | |
PEG Ratio | 0.24 | 0.07 | 0.00 | |
Price/Book | 4.1x | 2.7x | 2.6x | |
Price / LTM Sales | 3.3x | 67.0x | 3.4x | |
Upside (Analyst Target) | - | 251.2% | 35.7% | |
Fair Value Upside | Unlock | 5.2% | 4.1% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.000
(+444.75% Upside)
Earnings
Latest Release
Aug 14, 2025
EPS / Forecast
-0.04 / 0.11
Revenue / Forecast
25.77M / 23.10M
People Also Watch
FAQ
What Stock Exchange Does Protalix Trade On?
Protalix is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Protalix?
The stock symbol for Protalix is "PLX."
What Is the Protalix Market Cap?
As of today, Protalix market cap is 204.91M.
What Is Protalix's Earnings Per Share (TTM)?
The Protalix EPS (TTM) is 0.08.
When Is the Next Protalix Earnings Date?
Protalix will release its next earnings report on 16 Nov 2025.
From a Technical Analysis Perspective, Is PLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Protalix Stock Split?
Protalix has split 2 times.
How Many Employees Does Protalix Have?
Protalix has 213 employees.
What is the current trading status of Protalix (PLX)?
As of 09 Oct 2025, Protalix (PLX) is trading at a price of 2.570, with a previous close of 2.57. The stock has fluctuated within a day range of 2.530 to 2.599, while its 52-week range spans from 0.990 to 3.100.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.